4.5 Interaction with other medicinal products and other forms of interaction  
 Risankizumab is not expected to undergo metabolism by hepatic enzymes or renal elimination. Interactions between risankizumab and inhibitors, inducers, or substrates of medicinal product metabolising enzymes are not expected , and no dose adjustment is needed (see section 5.2).  
 Concomitant immunosuppressive therapy or phototherapy  
 The safety and efficacy of risankizumab in combination with immunosuppressants, including biologics or phototherapy, have not been evaluated.  
 
